In addition, combination of PI3K/mTOR inhibitor Gedatolisib plus Palbociclib and endocrine therapy in women with HR+/HER2-negative advanced breast cancer was well tolerated with an acceptable safety profile (41). Here, ERBB2 is linked to breast carcinoma.